| Name | Title | Contact Details |
|---|
Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles (EEV™), to engage intracellular targets that have long been considered inaccessible and undruggable. The Company`s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV Platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular disease, immunology, oncology and diseases of the central nervous system.
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company`s product candidates include FP-1039/GSK3052230, a protein therapeutic is in PhaseIb clinical trials for trapping and neutralizing cancer-promoting fibroblast growth factors (FGFs) involved in cancer cell proliferation and new blood vessel formation; FPA008, an antibody that inhibits colony stimulating factor-1 receptor; and FPA144 is an antibody for inhibiting FGF receptor 2b, as well as to treat patients with gastric cancer and potentially other solid tumors. It has collaboration and license agreements with GlaxoSmithKline LLC, Glaxo Group Limited, GSK-HGS, Pfizer Inc., and UCB Pharma S.A. The company was founded in 2001 and is headquartered in South San Francisco, California.
R2 Technology, Inc. is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CG Therapeutics Inc is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Argonaut Manufacturing Services provides contract manufacturing for pharmaceutical, diagnostics and life science organizations.